What are the Rome IV guidelines for diagnosing and treating irritable bowel syndrome and functional dyspepsia?

Rome IV Guidelines for IBS and Functional Dyspepsia

The Rome IV criteria are the current gold standard for diagnosing both irritable bowel syndrome (IBS) and functional dyspepsia (FD), though the Rome Foundation has acknowledged their restrictive nature and developed less stringent "clinical criteria" for routine practice. 1, 2

Diagnostic Criteria for Irritable Bowel Syndrome

Rome IV Criteria for IBS

IBS requires recurrent abdominal pain at least 1 day per week (increased from 3 days per month in Rome III) associated with two or more of the following 2:

• Related to defecation
• Associated with a change in stool frequency
• Associated with a change in stool form

Note that "discomfort" was removed from Rome IV, making the criteria more restrictive 3. This change means approximately 15% of Rome III IBS patients no longer meet diagnostic criteria 3.

IBS Subtypes

Patients are classified based on predominant stool pattern 2:

• IBS-D (diarrhea predominant)
• IBS-C (constipation predominant)
• IBS-M (mixed bowel habits)
• IBS-U (unclassified)

Clinical Reality vs. Research Criteria

The Rome IV criteria performed well in validation studies with 82.4% sensitivity and 82.9% specificity 4. However, they are more restrictive than Rome III, identifying patients with more severe symptoms, greater visceral hypersensitivity, and poorer quality of life 3. Recent research suggests that relaxing the pain frequency requirement back to 3 days per month improves diagnostic performance (sensitivity 90.2%, specificity 85.1%) 5.

Diagnostic Criteria for Functional Dyspepsia

Rome IV Criteria for FD

FD requires one or more of the following "bothersome" symptoms (severe enough to interfere with daily activities) 1:

• Epigastric pain
• Epigastric burning
• Postprandial fullness
• Early satiation

Plus:

• Symptom onset at least 6 months prior to diagnosis
• Symptoms active within the past 3 months
• No structural disease on upper endoscopy to explain symptoms

FD Subtypes

Two distinct subtypes exist 1:

Epigastric Pain Syndrome (EPS):

• Epigastric pain or burning at least 1 day per week
• Often present regardless of meals

Postprandial Distress Syndrome (PDS):

• Early satiation and/or postprandial fullness at least 3 times per week
• Triggered by meals

Important caveat: Patients frequently have overlapping EPS and PDS features, particularly in secondary/tertiary care 1.

Clinical Criteria for Routine Practice

The Rome Foundation developed less restrictive "clinical criteria" acknowledging that the 6-month onset requirement is impractical 1. These clinical criteria:

• Require cardinal symptoms present for only 8 weeks (not 6 months)
• Otherwise unchanged from Rome IV
• More applicable to real-world clinical practice

This modification addresses the criticism that Rome IV criteria have "much lower prevalence" in epidemiological studies and could "potentially delay diagnosis and subsequent treatment" 1.

Treatment Approach

Stepwise Management Algorithm (Both IBS and FD)

Step 1: Foundation 6

• Thorough doctor-patient discussion explaining diagnosis and prognosis
• Clarify therapy goals
• Lifestyle modifications
• Phytotherapeutics

Step 2: Symptom-Oriented Medication 6

For FD:

• PPIs (for epigastric pain/burning)
• Prokinetics (for postprandial symptoms)

For IBS:

• Antispasmodics (for pain)
• Secretagogues or laxatives (for IBS-C)
• Bile acid sequestrants or antidiarrheals (for IBS-D)
• Antibiotics (rifaximin for IBS-D)
• Probiotics

Step 3: Visceral Analgesics 6

• Low-dose tricyclic antidepressants
• Other neuromodulators

Critical Pitfalls

For FD: Do not confuse with gastroparesis—these are "symptom-based constructs with significant overlapping features" that cannot be distinguished by symptoms or gastric emptying studies alone. The term "FD with or without delayed gastric emptying" is preferable 1.

For IBS: The Rome IV criteria identify a more severe patient population than Rome III. Those meeting Rome IV criteria have significantly greater pain severity, bloating, somatization, fatigue, and rectal sensitivity 3. This means patients who no longer meet Rome IV criteria still have genuine symptoms requiring management.

Both conditions: Recognize that IBS and FD frequently overlap—patients with overlap have more severe symptoms 7. Most drug treatments remain off-label, and there is no FDA-approved drug specifically for functional dyspepsia 7.